Hematology

A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor (JAKi)-naïve myelofibrosis and moderate thrombocytopenia

Brief Summary: The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

Key Eligibility Criteria:

• A diagnosis of MF or post-ET or post-PV MF
• Measurable splenomegaly during the screening period 
• ECOG Performance Status less than or equal to (<=) 2
• More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase) excluded
• Previous treatment with JAK inhibitors for MF excluded
• Previous treatment with selinexor or other XPO1 inhibitors excluded